Myriad Genetics targets LabCorp with BRCA patent suit

This didn't take long. Myriad Genetics' ($MYGN) attorneys have struck again and filed a suit this time against LabCorp ($LH), barely two days after it launched a series of predictive cancer diagnostic tests focused on BRCA mutations. Genome Web reported that Myriad accuses LabCorp of violating 11 U.S. patents involving its tests that cover BRCA1 and BRCA2 mutations. Myriad has dominated the market, but the U.S. Supreme Court opened the door to competition over the summer with a ruling that invalidated some of its patents but upheld others. With LabCorp's entry into the space, there are now seven rivals marketing tests focused on BRCA mutations, and Myriad is suing all of them. Story (sub. req.)

Suggested Articles

The FDA has cleared its first fully disposable duodenoscope, following years of reports of infections being transmitted between patients.

OR-focused AI provider Caresyntax has garnered $45.6 million in new funding and picked up a data analytics firm to broaden its footprint.

A study of Foundation Medicine’s FoundationOne liquid biopsy test found it was able to predict the risk that a person’s breast cancer would return.